Clinical outcomes with first-line chemotherapy versus endocrine therapy for adjuvant endocrine therapy-resistant metastatic breast cancer

被引:0
作者
Shao, Bin [1 ]
Yang, Yanlian [2 ]
Qu, Jinrong [3 ]
Li, Huiping [1 ]
Song, Guohong [1 ]
Di, Lijun [1 ]
Jiang, Hanfang [1 ]
Yan, Ying [1 ]
Wang, Huan [1 ]
Liu, Xiaoran [1 ]
Wang, Jing [1 ]
Kong, Weiyao [1 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Med Oncol,Key Lab Carcinogenesis & Translat, Beijing 100142, Peoples R China
[2] CAS Ctr Excellence Nanosci, Natl Ctr Nanosci & Technol, CAS Key Lab Standardizat & Measurement Nanotechno, Beijing 100190, Peoples R China
[3] Shijiazhuang Third Hosp, Dept Oncol & Hematol, Shijiazhuang 050011, Hebei, Peoples R China
基金
北京市自然科学基金;
关键词
Endocrine resistance; ER+/HER2-; metastatic breast cancer (MBC); endocrine therapy (ET); chemotherapy (CT); PHASE-III; AROMATASE INHIBITORS; MAINTENANCE THERAPY; RANDOMIZED-TRIAL; MULTICENTER; CONSENSUS; BEVACIZUMAB; ANASTROZOLE; DOXORUBICIN; PACLITAXEL;
D O I
10.21037/tcr.2018.05.43
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Endocrine therapy resistance (ETR) is a great obstacle in the treatment of estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Patients with ETR have significantly decreased clinical benefit from endocrine therapy (ET). Therefore, it is quite important to find the clinicopathological factors that affect the outcome of patients with ETR in clinical practice. Method: We screened 405 consecutive ER+/HER2- metastatic breast cancer (MBC) patients who were treated from 2013-2015 in our hospital. Patients with ETR (defined as relapse during adjuvant ET or within 12 months after completing adjuvant ET) were selected to explore the clinicopathological factors affecting the objective response rate (ORR) and progression-free survival (PFS). Results: We included 135 patients in the study. Chemotherapy (CT) was administered to 96 patients and ET to 39 patients as first-line treatment. Patients with liver or visceral metastasis received CT significantly more frequently than ET (P=0.001, 0.001). There was no significant difference in median PFS between the two groups (ET: 11.8 months, CT: 12.0 months, P=0.667, HR =1.029). However, patients with more than two metastatic sites had a shorter PFS than patients with less than or equal to two metastatic sites (7.5 vs. 14.5 months, P=0.031, HR =1.714). When patients on CT were further stratified, those who received ET as maintenance therapy had a longer PFS (14.3 months) compared with those that did not (7.5 months) (P=0.003). Conclusions: ET and CT were both appropriate treatments for patients with ETR. Maintenance ET was a good choice for ER+/HER2- patients.
引用
收藏
页码:676 / 685
页数:10
相关论文
共 50 条
  • [11] Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer
    Mundhenke, Christoph
    Schem, Christian
    Jonat, Walter
    BREAST CARE, 2008, 3 (05) : 317 - 324
  • [12] First-Line Chemotherapy for Metastatic Breast Cancer
    Telli, Melinda L.
    Carlson, Robert W.
    CLINICAL BREAST CANCER, 2009, 9 : S66 - S72
  • [13] Extended adjuvant endocrine therapy of early breast cancer
    Chowdhury, S
    Ellis, P
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (12) : 1985 - 1995
  • [14] New options in adjuvant endocrine therapy in breast cancer
    Saltel-Fulero, Aurelien
    Donnadieu, Anne
    Leman-Detours, Solenne
    Cottu, Paul
    BULLETIN DU CANCER, 2016, 103 (01) : 104 - 112
  • [15] The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer
    Rinath Jeselsohn
    Carmine De Angelis
    Myles Brown
    Rachel Schiff
    Current Oncology Reports, 2017, 19
  • [16] A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy
    Polley, Mei-Yin C.
    Dickler, Maura N.
    Sinnwell, Jason
    Tenner, Kathleen
    de la Haba, Juan
    Loibl, Sibylle
    Goetz, Matthew P.
    Bergh, Jonas
    Roberston, John
    Couch, Fergus
    Ellis, Matthew J.
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 15 - 23
  • [17] The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer
    Jeselsohn, Rinath
    De Angelis, Carmine
    Brown, Myles
    Schiff, Rachel
    CURRENT ONCOLOGY REPORTS, 2017, 19 (05)
  • [18] Adjuvant endocrine therapy for early breast cancer
    Andreetta, Claudia
    Smith, Ian
    CANCER LETTERS, 2007, 251 (01) : 17 - 27
  • [19] Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis
    Bonotto, Marta
    Gerratana, Lorenzo
    Di Maio, Massimo
    De Angelis, Carmine
    Cinausero, Marika
    Moroso, Stefano
    Milano, Monica
    Stanzione, Brigida
    Gargiulo, Piera
    Iacono, Donatella
    Minisini, Alessandro Marco
    Mansutti, Mauro
    Fasola, Gianpiero
    De Placido, Sabino
    Arpino, Grazia
    Puglisi, Fabio
    BREAST, 2017, 31 : 114 - 120
  • [20] Adjuvant Endocrine Therapy for Early Breast Cancer: The Story So Far
    Gradishar, William J.
    CANCER INVESTIGATION, 2010, 28 (04) : 433 - 442